NovoCure
NovoCure

NovoCure

Health Care Equipment & Supplies
WebsiteInvestor RelationsSEC
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.

$1.8B

Market Cap • 9/25/2026

2000

(26 years)

Founded

2015

(11 years ago)

IPO

NASDAQ

Listing Exchange

Flag of Switzerland

Switzerland

Country

Valuation

P/B

5,5

P/S

2,6

P/EBITDA

—

P/OCF

—

P/FCF

—

P/E

—

BVPS

3

EPS

—

Market Cap

Market Cap

1,8B

EV

1,6B

EV/Revenue

2,3

EV/EBITDA

-11,9

EV/EBIT

-10,6

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

-0,4%

Total Yield

-0,4%

Payout

0%

Retained Earnings

-1,4B

Profitability

Gross Margin

76,1%

EBITDA Margin

—

EBIT Margin

—

Net Margin

—

D&A/EBITDA

0%

R&D/Revenue

32,1%

Capex/Revenue

3,2%

Capex/D&A

138,7%

Capex/OCF

-803,5%

SBC/OCF

—

% PPE

18,3%

% Goodwill

0%

ROE

—

ROIC

—

Growth

CAGR Revenue 5Y

5,1%

CAGR Net Income 5Y

100,6%

CAGR EPS 5Y

91,9%

Leverage

N.D./EBITDA

1,5

Debt/Equity

0%

Current Ratio

2,9

Quick Ratio

2,7

Interest Coverage

—

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium